680217-71-4

Basic information

• Product Name: ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE
• Synonyms: Ethyl (2,6-difluorophenyl)acetate, 2,6-Difluorophenylacetic acid ethyl ester
• CAS NO: 680217-71-4
• Molecular Formula: C₁₀H₁₀F₂O₂
• Molecular Weight: 200.1868
• Mol File: 680217-71-4.mol

Chemical Properties

• Boiling Point: 221.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE(680217-71-4)
• EPA Substance Registry System: ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE(680217-71-4)

Safety Data

• Hazardous Substances Data: 680217-71-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE is used as a reactant for the preparation of mono α-aryl derivatives of diethyl malonate and ethyl cyanoacetate using ethyl-α-imidazole carbamate. These derivatives are important intermediates in the synthesis of pharmaceutical compounds, as they can be further modified to produce a variety of drugs with different therapeutic properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE is utilized as a key building block for the creation of complex organic molecules. Its unique structure allows it to participate in various chemical reactions, such as coupling and condensation reactions, which can lead to the formation of new compounds with potential applications in various industries.
Used in Research and Development:
ETHYL 2-(2,6-DIFLUOROPHENYL)ACETATE is also used in research and development settings, where it can be employed to explore new synthetic routes and develop innovative methods for the preparation of pharmaceuticals and other organic compounds. Its unique structure and reactivity make it a valuable tool for chemists working on the design and synthesis of new molecules with potential applications in various fields.

Upstream product

• 85118-00-9 2,6-Difluorobenzyl bromide 
• 64-17-5 ethanol 
• 85068-28-6 2,6-difluorophenylacetic acid 

Downstream Products

• 1246200-00-9 6-(2,6-difluorophenyl)-8-methyl-2-(methylthio)pyrido-[2,3-d]pyrimidin-7(8H)-one 
• 1309752-62-2 2-(2,6-difluoro-3-nitrophenyl)ethyl acetate 
• 1309752-63-3 2-[2-({2-[(tert-butoxycarbonyl)amino]ethyl}amino)-6-fluoro-3-nitrophenyl]ethyl acetate 
• 1309752-66-6 tert-butyl [2-(2-phenyl-7,8-dihydro-1H-furo[3,2-e]benzimidazol-1-yl)ethyl]carbamate 
• 1309752-69-9 N-[2-(2-phenyl-7,8-dihydro-1H-furo[3,2-e]benzimidazol-1-yl)ethyl]acetamide 
• 168766-16-3 2-(2,6-difluorophenyl)ethanol 
• 1309752-61-1 2-(2,6-difluorophenyl)ethyl acetate 
• 359828-68-5 (2RS)-2-(2,6-difluorophenyl)propanoic acid 
• 116622-93-6 (2,6-difluorophenyl)acetic acid hydrazide 
• 1588424-32-1 C₁₆H₁₁ClF₂N₂O₂ 
• 1588423-56-6 C₂₀H₁₈ClF₂N₃O 
• 1588423-55-5 C₁₇H₁₃ClF₂N₂O 

Relevant articles and documents

Photocatalytic acyl azolium-promoted alkoxycarbonylation of trifluoroborates

Despite recent advancements in the selective generation and coupling of organic radical species, the alkoxycarbonyl radical remains underexplored relative to other carbon-containing radical species. Drawing inspiration from new strategies for generating acyl radical equivalents utilizing dual N-heterocyclic carbene catalysis and photocatalysis, we have prepared dimethylimidazolium esters that can function as an alkoxycarbonyl radical surrogate under photocatalytic conditions. We demonstrate the synthetic utility of these azolium-based partners through the preparation of esters arising from the coupling of this radical surrogate with an oxidatively generated alkyl radical.

2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists

A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists. The structure–activity analysis targeting their three pharmacophoric regions indicated that halogenated phenyl A-region analogs exhibited a broad functional profile ranging from agonism to antagonism. Among the compounds, antagonists 28 and 92 exhibited potent antagonism toward capsaicin for hTRPV1 with Ki[CAP] = 2.6 and 6.9 nM, respectively. Further, antagonist 92 displayed promising analgesic activity in vivo in both phases of the formalin mouse pain model. A molecular modeling study of 92 indicated that the two fluoro groups in the A-region made hydrophobic interactions with the receptor.

A novel serine racemase inhibitor suppresses neuronal over-activation in vivo

Serine racemase (SRR) is an enzyme that produces D-serine from L-serine. D-Serine acts as an endogenous coagonist of NMDA-type glutamate receptors (NMDARs), which regulate many physiological functions. Over-activation of NMDARs induces excitotoxicity, which is observed in many neurodegenerative disorders and epilepsy states. In our previous works on the generation of SRR gene knockout (Srr-KO) mice and its protective effects against NMDA- and Aβ peptide-induced neurodegeneration, we hypothesized that the regulation of NMDARs’ over-activation by inhibition of SRR activity is one such therapeutic strategy to combat these disease states. In the previous study, we performed in silico screening to identify four compounds with inhibitory activities against recombinant SRR. Here, we synthesized 21 derivatives of candidate 1, one of four hit compounds, and performed screening by in vitro evaluations. The derivative 13J showed a significantly lower IC50 value in vitro, and suppressed neuronal over-activation in vivo.

Synthesis of a novel series of tricyclic dihydrofuran derivatives: Discovery of 8,9-dihydrofuro[3,2-c ]pyrazolo[1,5-a ]pyridines as melatonin receptor (MT1/MT2) ligands

Novel tricyclic dihydrofuran derivatives were designed, synthesized, and evaluated as melatonin receptor (MT1/MT2) ligands based on the previously reported 1,6-dihydro-2H-indeno[5,4-b]furan 1a. By screening the central tricyclic cores, we identified 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a] pyridine as a potent scaffold with a high ligand-lipophilicity efficiency (LLE) value. Subsequent optimization of the side chains led to identification of the potent MT1/MT2 agonist 4d (MT1, Ki = 0.062 nM; MT2, Ki = 0.420 nM) with good oral absorption and blood-brain barrier (BBB) penetration in rats. The oral administration of compound 4d exhibited a sleep-promoting action in freely moving cats at 0.1 mg/kg.